
---
title: '靶向药物联合治疗在高度侵袭性脑瘤中显示高活性'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=8106'
author: 科学网
comments: false
date: Sat, 27 Nov 2021 10:33:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=8106'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">靶向药物联合治疗在一些高度侵袭性脑肿瘤中显示出前所未有的活性</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">据美国丹娜</span>-<span style="font-family: 宋体;">法伯癌症研究所（</span></span><a href="http://www.dana-farber.org/" target="_blank" style="font-size: 18px; font-family: "times new roman";">Dana-Farber Cancer Institute</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）</span>2021<span style="font-family: 宋体;">年</span>11<span style="font-family: 宋体;">月</span>25<span style="font-family: 宋体;">日提供的消息，靶向药物联合治疗在一些高度侵袭性脑肿瘤中显示出前所未有的活性（</span></span><a href="https://medicalxpress.com/news/2021-11-drug-combination-unprecedented-highly-aggressive.html" target="_blank" style="font-size: 18px; font-family: "times new roman";">Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）。丹娜</span>-<span style="font-family: 宋体;">法伯癌症研究所研究人员的一份临床试验报告显示，两种靶向癌症药物的联合治疗，在携带罕见基因突变的恶性脑肿瘤患者身上显示出前所未有的“有临床意义（</span>clinically meaningful<span style="font-family: 宋体;">）”的活性。相关研究结果于</span>2021<span style="font-family: 宋体;">年</span>11<span style="font-family: 宋体;">月</span>24<span style="font-family: 宋体;">日已经在《柳叶刀肿瘤学》（</span></span><a href="https://doi.org/10.1016/S1470-2045(21)00578-7" target="_blank" style="font-size: 18px; font-family: "times new roman";">The Lancet Oncology</a><span style="font-size: 18px; font-family: "times new roman";">）杂志网站发表——</span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Patrick Y Wen</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Alexander Stein</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Martin van den Bent</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Jacques De Greve</a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Antje Wick,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Filip Y F L de Vos,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Nikolasvon Bubnoff,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Myra Evan Linde,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Albert Lai,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Gerald W Prager,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Mario Campone,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Angelica Fasolo,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Jose A Lopez-Martin,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Tae Min Kim,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Warren P Mason,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Ralf-Dieter Hofheinz,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Jean-Yves Blay,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Daniel C Cho</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Anas Gazzah,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Damien Pouessel,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Jeffrey Yachnin,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Aislyn Boran,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Paul Burgess,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Palanichamy Ilankumaran,</a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Eduard Gasal,</a> <a href="https://www.sciencedirect.com/science/article/abs/pii/S1470204521005787?via%3Dihub#!" target="_blank" style="font-size: 18px; font-family: "times new roman";">Vivek Subbiah.</a><span style="font-size: 18px; font-family: "times new roman";"> Dabrafenib plus trametinib in patients with <em>BRAF</em><sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. </span><a href="https://doi.org/10.1016/S1470-2045(21)00578-7" target="_blank" style="font-size: 18px; font-family: "times new roman";">The Lancet Oncology</a><span style="font-size: 18px; font-family: "times new roman";"> (2021). </span><a href="http://dx.doi.org/10.1016/S1470-2045(21)00578-7" target="_blank" style="font-size: 18px; font-family: "times new roman";">DOI: 10.1016/S1470-2045(21)00578-7</a><span style="font-size: 18px; font-family: "times new roman";">. Available online 24 November 2021. </span><a href="https://doi.org/10.1016/S1470-2045(21)00578-7" target="_blank" title="Persistent link using digital object identifier" style="font-size: 18px; font-family: "times new roman";">https://doi.org/10.1016/S1470-2045(21)00578-7</a><span style="font-size: 18px; font-family: "times new roman";">.</span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">参与此项研究的除了来自丹娜</span>-<span style="font-size: 18px; font-family: 宋体;">法伯癌症研究所的研究人员之外，还有来自德国汉堡</span>-<span style="font-size: 18px; font-family: 宋体;">埃本多夫大学医学中心</span> (University Medical Center Hamburg-Eppendorf)<span style="font-size: 18px; font-family: 宋体;">、德国海德堡大学，德国国家肿瘤疾病中心（</span>University of Heidelberg, National Center for Tumor Diseases<span style="font-size: 18px; font-family: 宋体;">）、德国弗莱堡大学医学中心（</span>University Medical Center Freiburg<span style="font-size: 18px; font-family: 宋体;">）、德国石勒苏益格</span>-<span style="font-size: 18px; font-family: 宋体;">荷尔斯泰因大学医学中心（</span>Medical Center, University of Schleswig-Holstein<span style="font-size: 18px; font-family: 宋体;">）、德国曼海姆大学医院（</span>University Hospital of Mannheim<span style="font-size: 18px; font-family: 宋体;">）；荷兰鹿特丹大学医学中心（</span>University Medical Center Rotterdam<span style="font-size: 18px; font-family: 宋体;">）、荷兰乌德勒支大学医学中心（</span>University Medical Center Utrecht<span style="font-size: 18px; font-family: 宋体;">）、荷兰阿姆斯特丹自由大学（</span>Vrije Universiteit Amsterdam<span style="font-size: 18px; font-family: 宋体;">）；美国</span> <span style="font-size: 18px; font-family: 宋体;">加州大学洛杉矶分校（</span>University of California at Los Angeles<span style="font-size: 18px; font-family: 宋体;">）、美国纽约医学院（</span>New York Medical College<span style="font-size: 18px; font-family: 宋体;">）、美国东汉诺威的诺华制药公司（</span>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA<span style="font-size: 18px; font-family: 宋体;">）、美国德克萨斯大学安德森癌症中心（</span>The University of Texas MD Anderson Cancer Center<span style="font-size: 18px; font-family: 宋体;">）；法国圣赫布雷恩西部学院（</span>Institut de Cancérologie de l'Ouest, Saint-Herblain, France<span style="font-size: 18px; font-family: 宋体;">）、法国古斯塔夫·鲁西癌症研究所（</span>Gustave Roussy Cancer Institute<span style="font-size: 18px; font-family: 宋体;">）、法国图卢兹的癌症治疗中心（</span>Institut Universitaire du Cancer de Toulouse-Oncopole<span style="font-size: 18px; font-family: 宋体;">）、法国莱昂·贝拉德中心及克劳德·伯纳德里昂一世大学（</span>Center Leon Berard & University Claude Bernard Lyon I<span style="font-size: 18px; font-family: 宋体;">）；奥地利维也纳医科大学（</span>Medical University of Vienna<span style="font-size: 18px; font-family: 宋体;">）、比利时布鲁塞尔自由大学医院（</span>University Hospital Vrije Universiteit Brussel<span style="font-size: 18px; font-family: 宋体;">）、意大利米兰圣拉斐尔医院（</span>Ospedale San Raffaele IRCCS, Milan, Italy<span style="font-size: 18px; font-family: 宋体;">）、西班牙马德里国庆日大学医院及研究所（</span>12 de Octubre University Hospital & Research Institute, Madrid, Spain<span style="font-size: 18px; font-family: 宋体;">）、韩国首尔国立大学医院（</span>Seoul National University Hospital<span style="font-size: 18px; font-family: 宋体;">）、加拿大多伦多大学（</span>University of Toronto<span style="font-size: 18px; font-family: 宋体;">）、瑞典卡罗林斯卡大学医院（</span>Karolinska University Hospital<span style="font-size: 18px; font-family: 宋体;">）以及瑞士巴塞尔的诺华制药公司（</span>Novartis Pharma AG, Basel, Switzerland<span style="font-size: 18px; font-family: 宋体;">）的研究人员。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这种药物组合阻断了过度活跃的细胞生长信号通路，在</span>45<span style="font-size: 18px; font-family: 宋体;">名难以治疗的高级别胶质瘤（</span> </span><a href="https://medicalxpress.com/tags/high-grade+gliomas/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">high-grade gliomas</span></a><span style="font-size: 18px; font-family: "times new roman";">）患者（</span><a href="https://medicalxpress.com/tags/patients/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">patients</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）中，三分之一的患者的肿瘤缩小了</span>50%<span style="font-size: 18px; font-family: 宋体;">或更多，其中包括最具侵袭性的脑肿瘤——胶质母细胞瘤。之所以选择这些患者进行试验，是因为他们的肿瘤在</span>BRAF<span style="font-size: 18px; font-family: 宋体;">基因中携带了一种名为</span>v600E<span style="font-size: 18px; font-family: 宋体;">的基因突变。这种突变只在</span>2%- 3%<span style="font-size: 18px; font-family: 宋体;">的高级别胶质瘤患者中发现，但在</span>60%<span style="font-size: 18px; font-family: 宋体;">的低级别胶质瘤患者中发现。该研究包括</span>13<span style="font-size: 18px; font-family: 宋体;">例低级别胶质瘤患者。在这些患者中，</span>9<span style="font-size: 18px; font-family: 宋体;">名患者对联合用药的治疗有客观反应，有效率为</span>69%<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">达纳</span>-<span style="font-size: 18px; font-family: 宋体;">法伯神经肿瘤学中心（</span>Center for Neuro-Oncology at Dana-Farber<span style="font-size: 18px; font-family: 宋体;">）的主任、也是上述论文的第一作者</span>Patrick Wen<span style="font-size: 18px; font-family: 宋体;">医学博士说：“这是第一次有靶向药物在临床试验中被证明对胶质母细胞瘤有效。”他说，目前所有针对胶质母细胞瘤的化疗的有效率都不超过</span>5%<span style="font-size: 18px; font-family: 宋体;">，而联合化疗的有效率只有</span>33%<span style="font-size: 18px; font-family: 宋体;">。但</span>40<span style="font-size: 18px; font-family: 宋体;">岁以下患者的应答率甚至更高，约</span>40%<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在这项研究中，两种药物是达拉法尼（</span>dabrafenib<span style="font-size: 18px; font-family: 宋体;">）和曲美替尼（</span>trametinib<span style="font-size: 18px; font-family: 宋体;">）。这两种药物都以</span>MAPK<span style="font-size: 18px; font-family: 宋体;">通路（</span>MAPK pathway<span style="font-size: 18px; font-family: 宋体;">）中的蛋白质为靶点，</span>MAPK<span style="font-size: 18px; font-family: 宋体;">通路是一种蛋白信号链，充当细胞生长的开关，可能会卡在“开”的位置，导致不受控制的生长，导致肿瘤。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">3<span style="font-size: 18px; font-family: 宋体;">名患者有完全的反应，他们的肿瘤在影像学扫描上看不到，</span>12<span style="font-size: 18px; font-family: 宋体;">名患者的肿瘤有部分缩小。虽然患者未被治愈，但那些对药物有反应的人在一项评估中经历了显著的持久获益，中位反应持续时间为</span>13.6<span style="font-size: 18px; font-family: 宋体;">个月，另一项评估中为</span>36.9<span style="font-size: 18px; font-family: 宋体;">个月。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这些发现来自一项名为罕见肿瘤学不可知论研究</span>(Rare Oncology Agnostic Research<span style="font-size: 18px; font-family: 宋体;">简称</span>ROAR)<span style="font-size: 18px; font-family: 宋体;">的二期研究，该研究从</span>2014<span style="font-size: 18px; font-family: 宋体;">年开始在</span>13<span style="font-size: 18px; font-family: 宋体;">个国家的</span>27<span style="font-size: 18px; font-family: 宋体;">个社区和学术癌症中心招募患者。这项研究是一项所谓的“篮子”试验（</span>"basket" trial<span style="font-size: 18px; font-family: 宋体;">），旨在招募具有共同肿瘤特征</span>(<span style="font-size: 18px; font-family: 宋体;">在本例中为</span>BRAF v600E<span style="font-size: 18px; font-family: 宋体;">突变</span>)<span style="font-size: 18px; font-family: 宋体;">的患者，尽管他们可能患有一系列不同的癌症。</span>ROAR<span style="font-size: 18px; font-family: 宋体;">研究包括甲状腺癌（</span>thyroid cancer<span style="font-size: 18px; font-family: 宋体;">）和胆道癌（</span>biliary tract cancer<span style="font-size: 18px; font-family: 宋体;">）、胃肠道间质瘤（</span>gastrointestinal stromal tumors<span style="font-size: 18px; font-family: 宋体;">）、毛细胞白血病（</span>hairy cell leukemia<span style="font-size: 18px; font-family: 宋体;">）、多发性骨髓瘤（</span>multiple myeloma<span style="font-size: 18px; font-family: 宋体;">）、低级别和高级别胶质瘤脑瘤（</span>low- and high-grade </span><a href="https://medicalxpress.com/tags/glioma/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">glioma</span></a><span style="font-size: 18px; font-family: "times new roman";"> brain tumors<span style="font-size: 18px; font-family: 宋体;">）等患者。该研究旨在确定达拉法尼联合曲美替尼在</span>BRAF v600e<span style="font-size: 18px; font-family: 宋体;">突变癌症患者中的总有效率。</span>BRAF<span style="font-size: 18px; font-family: 宋体;">蛋白是一种生长信号蛋白激酶，在调节</span>MAPK<span style="font-size: 18px; font-family: 宋体;">信号通路中发挥作用。</span>BRAF v600E<span style="font-size: 18px; font-family: 宋体;">突变通过激活</span>MAPK<span style="font-size: 18px; font-family: 宋体;">通路</span>(<span style="font-size: 18px; font-family: 宋体;">由许多蛋白质组成</span>)<span style="font-size: 18px; font-family: 宋体;">驱动癌症，导致细胞生长（</span></span><a href="https://medicalxpress.com/tags/cell+growth/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">cell growth</span></a><span style="font-size: 18px; font-family: "times new roman";">）失控和肿瘤（</span><a href="https://medicalxpress.com/tags/tumor/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">tumor</span></a><span style="font-size: 18px; font-family: "times new roman";">）的发展。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在这项研究中使用的药物，达拉法尼和曲美替尼，是阻断部分过度活跃的</span>MAPK<span style="font-size: 18px; font-family: 宋体;">信号通路的口服药物。达拉法尼抑制一种酶，</span>B-Raf<span style="font-size: 18px; font-family: 宋体;">，而曲美替尼抑制分子</span>MEK1<span style="font-size: 18px; font-family: 宋体;">和</span>MEK2<span style="font-size: 18px; font-family: 宋体;">，它们是</span>MAPK<span style="font-size: 18px; font-family: 宋体;">途径的一部分。它们已被用于联合治疗黑色素瘤、非小细胞肺癌和甲状腺癌。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">神经胶质瘤是起源于神经胶质的癌症，是大脑的支持细胞，而不是大脑神经元本身。神经胶质瘤占所有恶性脑肿瘤（</span><a href="https://medicalxpress.com/tags/malignant+brain+tumors/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">malignant brain tumors</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）的</span>80%<span style="font-size: 18px; font-family: 宋体;">。一些是生长缓慢的低级别胶质瘤，而另一些是侵袭性的高级别胶质瘤，包括难以移除且几乎总是复发的胶质母细胞瘤。该报告的作者说，近年来在治疗胶质瘤方面没有重大进展，但有个别报告显示，达拉法尼和曲美替尼联合治疗胶质瘤表现出活性。他们在</span>ROAR<span style="font-size: 18px; font-family: 宋体;">研究中的报告“是</span>BRAF<span style="font-size: 18px; font-family: 宋体;">抑制剂</span>(dabrafenib)<span style="font-size: 18px; font-family: 宋体;">和</span>MEK<span style="font-size: 18px; font-family: 宋体;">抑制剂</span>(trametinib)<span style="font-size: 18px; font-family: 宋体;">的组合首次在这些难以治疗的胶质瘤中显示出显著的活性，包括历史上显示了治疗耐药性的恶性胶质瘤（</span>glioblastomas<span style="font-size: 18px; font-family: 宋体;">）。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">虽然这些药物只帮助了携带罕见</span>V600E<span style="font-size: 18px; font-family: 宋体;">突变的肿瘤患者，但温说，结果令人鼓舞，“因为人们开始认为，永远不会有任何针对胶质母细胞瘤的靶向治疗。”他补充说，有新的证据表明，在神经胶质瘤中可能有其他的靶点可以被设计药物阻断。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://doi.org/10.1016/S1470-2045(21)00578-7" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://medicalxpress.com/news/2021-11-drug-combination-unprecedented-highly-aggressive.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-11-practice-changing-trial-results-advanced-melanoma.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Practice-changing trial results for advanced melanoma skin cancer</span></a></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/S1470-2045(21)00578-7" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;" target="_blank"><span style="font-family: "arial black", "avant garde";"><strong>Summary</strong></span></a><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>Background</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Effective treatments are needed to improve outcomes for high-grade </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/glioblastoma" title="Learn more about glioma from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">glioma</span></a><span style="font-size: 18px; font-family: "times new roman";"> and low-grade glioma. The activity and safety of </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/dabrafenib" title="Learn more about dabrafenib from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">dabrafenib</span></a><span style="font-size: 18px; font-family: "times new roman";"> plus </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/trametinib" title="Learn more about trametinib from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">trametinib</span></a><span style="font-size: 18px; font-family: "times new roman";"> were evaluated in adult patients with recurrent or progressive <em>BRAF</em><sup>V600E</sup> mutation-positive high-grade glioma and low-grade glioma.</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>Methods</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial at 27 community and academic cancer centres in 13 countries (Austria, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, and the USA). The study enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Patients with BRAFV600E mutation-positive high-grade glioma and low-grade glioma received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally until unacceptable toxicity,</span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/disease-exacerbation" title="Learn more about disease progression from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">disease progression</span></a><span style="font-size: 18px; font-family: "times new roman";">, or death. In the high-grade glioma cohort, patients were required to have measurable disease at baseline using the Response Assessment in Neuro-Oncology high-grade glioma response criteria and have been treated previously with radiotherapy and first-line chemotherapy or concurrent</span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/chemoradiotherapy" title="Learn more about chemoradiotherapy from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">chemoradiotherapy</span></a><span style="font-size: 18px; font-family: "times new roman";">. Patients with low-grade glioma were required to have measurable non-enhancing disease (except pilocytic astrocytoma) at baseline using the Response Assessment in Neuro-Oncology low-grade glioma criteria. The primary endpoint, in the evaluable intention-to-treat population, was investigator-assessed objective response rate (complete response plus partial response for high-grade glioma and complete response plus partial response plus minor response for low-grade glioma). This trial is ongoing, but is closed for enrolment, </span><a href="https://clinicaltrials.gov/show/NCT02034110" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">NCT02034110</span></a><span style="font-size: 18px; font-family: "times new roman";">.</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>Findings</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Between April 17, 2014, and July 25, 2018, 45 patients (31 with glioblastoma) were enrolled into the high-grade glioma cohort and 13 patients were enrolled into the low-grade glioma cohort. The results presented here are based on interim analysis 16 (data cutoff Sept 14, 2020). In the high-grade glioma cohort, median follow-up was 12·7 months (IQR 5·4–32·3) and 15 (33%; 95% CI 20–49) of 45 patients had an objective response by investigator assessment, including three complete responses and 12 partial responses. In the low-grade glioma cohort, median follow-up was 32·2 months (IQR 25·1–47·8). Nine (69%; 95% CI 39–91) of 13 patients had an objective response by investigator assessment, including one complete response, six partial responses, and two minor responses. Grade 3 or worse adverse events were reported in 31 (53%) patients, the most common being fatigue (five [9%]), decreased </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/neutrophil" title="Learn more about neutrophil from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">neutrophil</span></a><span style="font-size: 18px; font-family: "times new roman";"> count (five [9%]), headache (three [5%]), and neutropenia (three [5%]).</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong>Interpretation</strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Dabrafenib plus trametinib showed clinically meaningful activity in patients withBRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications.BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma.</span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1314093.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1314093.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1313907.html" target="_black">研究预测了超导体中近藤云的行为</a><br>                    <!--大赛结束-->
                                        
  
</div>
            